Irino Tomoyuki, Takeuchi Hiroya, Matsuda Sachiko, Saikawa Yoshiro, Kawakubo Hirofumi, Wada Norihito, Takahashi Tsunehiro, Nakamura Rieko, Fukuda Kazumasa, Omori Tai, Kitagawa Yuko
Department of Surgery, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku Tokyo 160-8582, Japan.
BMC Cancer. 2014 Apr 26;14:291. doi: 10.1186/1471-2407-14-291.
CC-chemokine receptor 7 (CCR7), a known lymph node homing receptor for immune cells, has been reported as a key molecule in lymph node metastasis. We hypothesized a clinicopathological correlation and functional causality between CCR7 expression and lymph node metastasis in patients with esophageal squamous cell carcinoma (ESCC).
We performed immunohistochemical analysis of 105 consecutive and 61 exclusive pathological T1 ESCC patients, followed by adhesion assay and in vivo experiment using a newly developed lymph node metastasis mouse model. The adhesive ability in response to CC-chemokine ligand 21/secondary lymphoid-tissue chemokine (CCL21/SLC) was assessed in the presence or absence of lymphatic endothelial cells and anti-CCR7 antibody. We established a heterotopic transplantation mouse model and analyzed lymph node metastasis by quantitative real-time RT-PCR.
Positive CCR7 expression in immunohistochemistory was detected in 28 (27%) of 105 consecutive patients and 17 (28%) of 61 T1 patients, which significantly correlated with lymph node metastasis (p = 0.037 and p = 0.040, respectively) and poor five-year survival (p = 0.013 and p = 0.012, respectively). Adhesion assay revealed an enhanced adhesive ability of CCR7-expressing cells in response to CCL21/SLC, in particular, in the presence of lymphatic endothelial cells (p = 0.005). In the mouse model, lymph nodes from mice transplanted with CCR7-expressing cells showed significantly higher DNA levels at 5 weeks (p = 0.019), indicating a high metastatic potential of CCR7-expressing cells.
These results demonstrated the significant clinicopathological relationship and functional causality between CCR7 expression and lymph node metastasis in ESCC patients.
CC趋化因子受体7(CCR7)是一种已知的免疫细胞淋巴结归巢受体,据报道是淋巴结转移中的关键分子。我们推测食管鳞状细胞癌(ESCC)患者中CCR7表达与淋巴结转移之间存在临床病理相关性和功能因果关系。
我们对105例连续的和61例单纯病理T1期ESCC患者进行了免疫组织化学分析,随后使用新开发的淋巴结转移小鼠模型进行了黏附试验和体内实验。在有或无淋巴管内皮细胞及抗CCR7抗体的情况下,评估对CC趋化因子配体21/二级淋巴组织趋化因子(CCL21/SLC)的反应中的黏附能力。我们建立了异位移植小鼠模型,并通过定量实时逆转录聚合酶链反应分析淋巴结转移情况。
在105例连续患者中有28例(27%)和61例T1期患者中有17例(28%)在免疫组织化学中检测到CCR7表达阳性,这与淋巴结转移(分别为p = 0.037和p = 0.040)及五年生存率低(分别为p = 0.013和p = 0.012)显著相关。黏附试验显示,表达CCR7的细胞对CCL21/SLC的反应中黏附能力增强,特别是在有淋巴管内皮细胞存在的情况下(p = 0.005)。在小鼠模型中,移植表达CCR7细胞的小鼠的淋巴结在5周时显示出显著更高的DNA水平(p = 0.019),表明表达CCR7的细胞具有高转移潜能。
这些结果证明了ESCC患者中CCR7表达与淋巴结转移之间存在显著的临床病理关系和功能因果关系。